Newly released draft guidance from FDA underscores the agency’s increasing reliance on maximal usage trials (MUsTs) to support topical ingredients’ inclusion in OTC drug monographs.
The document could have more companies contemplating new drug approval pathways as an alternative to generally recognized as safe and...



